Einloggen
E-Mail
Passwort
Passwort anzeigen
Merken
Passwort vergessen?
Watchlisten für Ihre Werte
Registrieren
Registrieren
Mitglied werden
Kostenlos registrieren
Abonnent werden
Unser Angebot
Einstellungen
Einstellungen
Dynamische Kurse 
OFFON

ELI LILLY AND COMPANY

(LLY)
  Bericht
ÜbersichtKurseChartsNewsRatingsTermineUnternehmenFinanzenAnalystenschätzungenRevisionenDerivate 
ÜbersichtAlle NewsAnalystenempfehlungenAndere SprachenPressemitteilungenOffizielle PublikationenBranchen-News
Nachrichten in anderen Sprachen über ELI LILLY AND COMPANY
03.12.FDA adds strict safety warnings on arthritis drugs from Pfizer, AbbVie and Lilly
03.12.Eli Lilly, AbCellera Land FDA's Expanded Emergency Use Approval for COVID-19 Antibody T..
03.12.Eli Lilly Gets FDA's Expanded Emergency Use Approval for Antibody Therapy to Treat COVI..
03.12.FDA Expands Emergency Use for Lilly Antibody Combination for Covid-19 to Include Infant..
03.12.Eli Lilly Sees FDA Granting EUA of Two Monoclonal Antibodies for Treatment of COVID in ..
03.12.AbCellera Biologics Names New Chief Commercial Officer
03.12.Eli Lilly, Innovent Biologics' Cancer Drug Added to China's Updated National Reimbursem..
03.12.Biotech Growth Stocks Set to Benefit from Rising Volatility (REGN, OTLC, AMGN, ILMN, LL..
03.12.Innovent Biologics, Inc. and Eli Lilly and Company Announce Successful Expansion of Sin..
02.12.Special Report-U.S. rushed contracts to COVID-19 suppliers with troubled plants
02.12.What COVID-19 vaccine and drug makers have to say about Omicron
01.12.Lilly to Announce Initial 2022 Financial Guidance; Provide R&D Overview at Investment C..
30.11.US Stocks Slump as Omicron Variant, Fed Chief's Comment on Faster Asset Purchase Taperi..
30.11.CLOSE UPDATE : US Stocks See Sharp Decline as Omicron Variant, Fed Chief Comment on Faster..
30.11.Equities Drop Midday as Moderna CEO Questions COVID-19 Vaccines' Efficacy Against Omicr..
30.11.MIDDAY REPORT : US Stocks Drop as Moderna CEO Questions COVID-19 Vaccines' Efficacy Agains..
30.11.Regeneron's COVID-19 antibody drug may be less effective against Omicron
18.11.Emgality Versus Nurtec ODT Head-To-Head Migraine Preventive Treatment Study Now Enrolli..
18.11.Fountain Therapeutics Inc. announced that it has received $15.864168 million in funding..
17.11.Lilly to Participate in Fourth Annual Evercore ISI HealthCONx Conference
17.11.PharmStars Announces Showcase Event for Inaugural Class
16.11.Fountain Therapeutics Inc. announced that it expects to receive $15.864168 million in f..
12.11.REFILE-UPDATE 4-Biden will nominate industry-friendly Califf to lead U.S. FDA
12.11.Dicerna Pharmaceuticals to Receive Multimillion-Dollar Milestone Payments Under Collabo..
12.11.Lilly to supply 614,000 additional doses of abcellera, discovered bamlanivimab together..
12.11.DICERNA PHARMA : Two Targets in Lilly Collaboration Meet Proof of Principle
12.11.Dicerna Pharmaceuticals, Inc. Announces Two Targets Meet Preclinical Proof of Principle..
12.11.ELI LILLY : procédure d'examen prioritaire pour Jardiance
11.11.Health Care Down As Traders Hedge On Growth View -- Health Care Roundup
11.11.Eli Lilly, Boehringer's Heart Drug Jardiance Gets Priority Review from FDA
11.11.US FDA accepts supplemental New Drug Application and grants Priority Review for Jardian..
11.11.Boehringer Ingelheim and Eli Lilly and Company Announces US FDA Accepts Supplemental Ne..
11.11.District Courts Issue Key Decisions In 340B Contract Pharmacy Cases
09.11.Lilly to Participate in Wolfe Research Virtual Healthcare Conference
02.11.Eli Lilly to Supply COVID-19 Medication Worth $1.29 Billion as Part of Additional US Go..
02.11.Eli Lilly Withdraws From European Medicines Agency's Rolling Review Process for COVID-1..
02.11.ELI LILLY : fin de l'examen continu de deux anticorps Covid
02.11.Monetary policy starts to change
02.11.ELI LILLY : contrat de 1,23 Md$ avec le gouvernement US
02.11.Eli Lilly to Supply $1.29 Billion Worth of COVID-19 Medication as Part of Additional US..
02.11.Eli Lilly Gets $1.29 Billion U.S. Order for Covid-19 Cocktail
02.11.U.S. buys more doses of Lilly's COVID-19 treatment for $1.29 bln
02.11.U.S. buys more doses of Lilly's COVID-19 treatment for $1.29 bln
02.11.Eli Lilly and Company to Supply 614,000 Additional Doses of Bamlanivimab and Etesevimab..
01.11.Lilly to Participate in Bernstein's Second Annual Operational Decisions Conference
29.10.Fabricants de médicaments contre les troubles érectiles condamnés
28.10.Additional Verzenio® (abemaciclib) Phase 3 monarchE Trial Data Published in the Annals ..
27.10.ELI LILLY & CO Management's Discussion and Analysis of Results of Operations and Finan..
26.10.Eli Lilly Reports Higher Third-Quarter Results, Raises 2021 Forecast to Reflect Increas..
26.10.GLOBAL MARKETS LIVE : Michelin, Facebook, UBS, Tesla, Volvo...
26.10.Eli Lilly Intends to Complete US Marketing Application Submission for Alzheimer's Drug ..
26.10.Eli Lilly Alzheimer's Programs Head in Different Directions
26.10.Health Care Stocks Edge Higher Premarket Tuesday
26.10.Eli Lilly, Pfizer Halt Program for Osteoarthritis Pain Drug
26.10.Les valeurs à suivre aujourd'hui à Wall Street Mardi 26 octobre 2021
26.10.Lilly kicks off application for Alzheimer's drug U.S. approval, ups outlook
26.10.Eli Lilly relève son objectif de ventes 2021
26.10.Are companies fooling themselves on inflation?
26.10.ELI LILLY : hausse de 38% du BPA au 3e trimestre
26.10.Lilly Cuts Income Targets, Lifts Sales Forecast For FY21
26.10.Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthe..
26.10.Eli Lilly past outlook aan
26.10.Q3 2021 Lilly Press Release
26.10.Eli Lilly Posts Higher Q3 Adjusted EPS, Revenue; Boosts 2021 Guidance
26.10.LILLY : Q3 Earnings Snapshot
26.10.Earnings Flash (LLY) ELI LILLY AND COMPANY Reports Q3 Revenue $6.77B, vs. Street Est of..
26.10.GUIDANCE : (LLY) ELI LILLY AND COMPANY Expects Fiscal Year 2021 EPS Range $7.95 - $8.05
26.10.Lilly Reports Robust Third-Quarter 2021 Financial Results as Pipeline Success Strengthe..
26.10.Earnings Flash (LLY) ELI LILLY AND COMPANY Reports Q3 EPS $1.94, vs. Street Est of $1.9..
26.10.Eli Lilly and Company Revises Earnings Guidance for the Full Year 2021
26.10.EARNINGS REACTION HISTORY : Eli Lilly and Co, 33.3% Follow-Through Indicator, 2.2% Sensiti..
26.10.Eli Lilly, Pfizer End Program for Tanezumab Pain Drug
26.10.Eli Lilly Moves Forward With Diabetes, Alzheimer's Drugs
26.10.Tesla y Facebook en modo fuego cruzado
26.10.Tesla et Facebook en mode chassé-croisé
1  2  3  4  5  6  7  8  9  10Weiter